KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Debt to Equity (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Debt to Equity readings, the most recent being -$0.32 for Q4 2025.

  • On a quarterly basis, Debt to Equity rose 55.8% to -$0.32 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.32, a 55.8% increase, with the full-year FY2025 number at -$0.32, up 55.8% from a year prior.
  • Debt to Equity hit -$0.32 in Q4 2025 for Biocryst Pharmaceuticals, up from -$0.6 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of -$0.32 in Q4 2025 to a low of -$1.64 in Q1 2021.
  • Median Debt to Equity over the past 5 years was -$0.74 (2024), compared with a mean of -$0.82.
  • The widest YoY moves for Debt to Equity: up 79.54% in 2021, down 165.61% in 2021.
  • Biocryst Pharmaceuticals' Debt to Equity stood at -$1.27 in 2021, then surged by 38.19% to -$0.79 in 2022, then increased by 8.76% to -$0.72 in 2023, then dropped by 1.79% to -$0.73 in 2024, then surged by 55.8% to -$0.32 in 2025.
  • The last three reported values for Debt to Equity were -$0.32 (Q4 2025), -$0.6 (Q3 2025), and -$0.66 (Q2 2025) per Business Quant data.